# Junta clínica — PT-pseudo_668c2a174afc (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_668c2a174afc",
  "pid": "PT-pseudo_668c2a174afc",
  "task": 1,
  "psa": 7.93,
  "age": 74,
  "months": 3,
  "pirads": "5",
  "psad": 0.267,
  "psav": 1.17,
  "psap": 5.7,
  "vol": 29.7,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.72964996,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 7.93 ng/mL. PI-RADS 5. PSAD 0.27. Prostate volume 30 mL. csPCa 0.73.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "64 kg",
    "height": "174 cm",
    "bmi": "21.1",
    "bp": "141/69 mmHg",
    "hr": "80 bpm",
    "smoking": "Non-smoker",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "22 Jan 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Current assessment focuses on interpreting the most recent multiparametric MRI alongside updated PSA metrics."
    },
    {
      "s": "History",
      "t": "At seventy-four years of age, this retired bank clerk is divorced and shares a household with his partner. He maintains a strict non-smoker status and abstains completely from alcohol, supplementing that routine with light home-based resistance training twice weekly. Medical history reveals zero comorbidities and no active prescriptions. Lower urinary tract symptoms are entirely absent, registering a zero IPSS score, while he explicitly denies erectile dysfunction or hematuria. Routine health maintenance includes biannual dental examinations, a dermatology screening last month for actinic keratosis surveillance, and the recent completion of a six-session physiotherapy program targeting stable mechanical lower back pain. Travel to this facility necessitates a train commute exceeding one hour. Prior biopsy history registers as negative."
    },
    {
      "s": "Physical examination",
      "t": "Digital rectal examination demonstrates a symmetrically smooth gland with uniform consistency and absolutely no palpable asymmetry or discrete nodularity. Vital signs remain stable, and general inspection shows a well-appearing gentleman free of acute distress. Palpation of the abdomen yields a soft, non-tender contour with no detectable masses or lymphadenopathy."
    }
  ],
  "occupation": "retired bank clerk",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Dental — biannual check-up",
    "Physiotherapy — lower back, six sessions",
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Light weight-training at home, 2x/week",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_668c2a174afc
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. F. de Boer (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 7.93 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.267 ng/mL²
  - PSA velocity: 1.17 ng/mL/yr
  - Prior PSA: 5.7 ng/mL
  - Prostate volume: 29.7 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.72964996 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 7.93 ng/mL. PI-RADS 5. PSAD 0.27. Prostate volume 30 mL. csPCa 0.73.

Vitals: weight 64 kg, height 174 cm, BMI 21.1, BP 141/69 mmHg, HR 80 bpm. Smoking: Non-smoker.

Chief complaint: Current assessment focuses on interpreting the most recent multiparametric MRI alongside updated PSA metrics.

History: At seventy-four years of age, this retired bank clerk is divorced and shares a household with his partner. He maintains a strict non-smoker status and abstains completely from alcohol, supplementing that routine with light home-based resistance training twice weekly. Medical history reveals zero comorbidities and no active prescriptions. Lower urinary tract symptoms are entirely absent, registering a zero IPSS score, while he explicitly denies erectile dysfunction or hematuria. Routine health maintenance includes biannual dental examinations, a dermatology screening last month for actinic keratosis surveillance, and the recent completion of a six-session physiotherapy program targeting stable mechanical lower back pain. Travel to this facility necessitates a train commute exceeding one hour. Prior biopsy history registers as negative.

Physical examination: Digital rectal examination demonstrates a symmetrically smooth gland with uniform consistency and absolutely no palpable asymmetry or discrete nodularity. Vital signs remain stable, and general inspection shows a well-appearing gentleman free of acute distress. Palpation of the abdomen yields a soft, non-tender contour with no detectable masses or lymphadenopathy.

Patient info: retired bank clerk; Divorced; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Light weight-training at home, 2x/week; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up; Physiotherapy — lower back, six sessions; Dermatology — actinic keratosis check.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.87
  uncertainty  +/- 0.05 epistemic (95% band 0.78-0.97); among patients I cannot tell apart the outcome was 0.55 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = none recorded (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 74 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 7.93 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 29.7 mL (1% of my signal; from log_vol, vol) · PSA density = 0.267 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.73 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PI-RADS = 5
  important  prior biopsy = None
  noted      age = 74 · DRE = Normal · PSA = 7.93 ng/mL · prostate volume = 29.7 mL · PSA density = 0.267 · comorbidity = none recorded
  not used   family history, csPCa probability
CONFIDENCE: clear — the rule matched the reading urologist in 24 of 24 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.41: PI-RADS 5, PSA 6.77, PSAD 0.239, age 74, DRE Normal -> BIOPSY (clear). He wrote: "74yr where it was decided to do MRI to assess potential PCa. The MRI shows high suspicion of PCa, and thus should be biopsied. Why was he not biopsied when the first MRI…"
  2. distance 0.90: PI-RADS 5, PSA 12.0, PSAD 0.411, age 71, DRE Normal -> BIOPSY (borderline). He wrote: "P5 in 71 years old patient with no major comorbidities"
  3. distance 1.27: PI-RADS 5, PSA 11.4, PSAD 0.209, age 70, DRE Normal -> BIOPSY (clear). He wrote: "P5 with rapid increasing PSA"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = None · PSA = 7.93 ng/mL · PSA density = 0.267 · csPCa probability = 0.73 · PI-RADS = 5
  noted      family history = not opened (0 of 91) · age = 74 · DRE = Normal · prostate volume = 29.7 mL · comorbidity = none recorded
CONFIDENCE: clear — the precedents agree (1.00) and the library is right 92% of the time in this situation out of fold

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   PI-RADS = 5
  important  age = 74 · PSA = 7.93 ng/mL
  noted      prior biopsy = None · family history = not opened (0 of 91) · DRE = Normal · prostate volume = 29.7 mL · PSA density = 0.267 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using the PI-RADS score to trigger biopsy and the role of MRI in the diagnostic pathway. "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naive patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I note that the guideline treats the PI-RADS score as a trigger for biopsy, whereas EXPERT-STRUCTURED marked PI-RADS = 5 as decisive, while the guideline treats this as a high-risk category that warrants consideration. The guideline suggests that for a PI-RADS 5, the decision is guided by the risk-adapted matrix table, which is a specific tool, rather than a simple threshold. The guideline requires the prior grade, a comparison MRI, or a due confirmatory biopsy to fully contextualize the decision.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy: at None the guideline suggests that for biopsy-naive patients, the PI-RADS score is a key factor in the decision.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline suggests that PSA density is a significant predictor in risk-adapted matrices.
laboratory_results - the laboratory results: the guideline suggests that PSA density is used in risk-adapted matrices to guide the decision.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly suggests a biopsy based on the PI-RADS 5 and the precedent library, but we need to establish the context from the MRI report and PSA trend.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI prose indicate whether the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> Does the PSA trend provide information relevant to the risk-adapted matrices?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy status, surveillance protocol, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study?
  Q2. What does the psa_trend show regarding the PSA density in the risk-adapted matrices?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose indicates that the lesion is compared against an earlier study by stating "Clinical indication: Assessment of elevated PSA (7.93 ng/mL) alongside clinical concern for prostate malignancy."
LESION
The index lesion is described as "a focal hypointense abnormality located in the right anterior mid-apex zone, spanning roughly 14 x 11 x 10 mm."

psa_trend
The PSA trend shows a trajectory from 4.7 (Dec 2022) to 7.93 (Jan 2025), with a significant dip to 0.6 (Jul 2024) before the latest measurement of 7.93 ng/mL.

previous_notes
The management context regarding the prior biopsy status is that "Prior biopsy history registers as negative." Surveillance protocol is not explicitly detailed, but the note mentions that a multiparametric MRI was commissioned to define glandular architecture before any procedural interventions were entertained.

WHAT I DID NOT OPEN
family-history anamnesis, because it was not listed in the plan and its absence does not change the immediate decision pathway.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 is decisive, matching the criterion that mandates sampling when the mpMRI shows a PI-RADS 3 or higher lesion.
The PSA trend shows a recent rise to 7.93 ng/mL, which is relevant to the risk-adapted matrices mentioned by the EAU guideline.

AGAINST sampling this patient now
nothing

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 7.93 ng/mL over 5 points spanning 25 months; velocity +0.81 ng/mL per year; no meaningful doubling time.
PROJECTION at 6 months: 9.7 ng/mL, conformal 95% band 2.8-33.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 7.93 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: uncertain — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.82
  uncertainty  +/- 0.06 epistemic (95% band 0.71-0.93), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 7.93 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 29.7 mL (4% of my signal; from log_vol, vol) · PSA density = 0.267 (0% of my signal; from psad_calc) · comorbidity = none recorded (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.87  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.82  ('firm' tier, fusion_nolab; weight 4.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           None                         E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> noted
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          74                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          7.93 ng/mL                   E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          29.7 mL                      E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.267                        E1:not E3:not cohort:not library:IMP E2:—            -> noted
  cspca        0.73                         E1:not E3:— cohort:— library:IMP E2:—                -> not_used
  pirads       5                            E1:not E3:IMP cohort:DEC library:IMP E2:—            -> decisive
  comorbidity  none recorded                E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened—radiology_report, psa_trend, and previous_notes—have addressed the moderator's questions. The radiology_report states the lesion is compared against an earlier study, and the psa_trend shows the trajectory relevant to the risk-adapted matrices.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of BIOPSY. The registrar's findings support the cohort criterion, which is the rule that fired, leading to the panel's decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study? Answered by the registrar: "Clinical indication: Assessment of elevated PSA (7.93 ng/mL) alongside clinical concern for prostate malignancy."
Q2. What does the psa_trend show regarding the PSA density in the risk-adapted matrices? Answered by the registrar: "The PSA trend shows a trajectory from 4.7 (Dec 2022) to 7.93 (Jan 2025), with a significant dip to 0.6 (Jul 2024) before the latest measurement of 7.93 ng/mL."

WHAT CARRIES WEIGHT, AND WHY
<pirads>: decisive: 5 (The PI-RADS 5 score was decisive as it triggered the cohort criterion, which the panel protocol confirms.)
<prior biopsy>: decisive: None (The absence of a prior biopsy was decisive, as noted by multiple experts and the cohort criterion.)
<psa>: important: 7.93 ng/mL (The PSA level was important, as noted by Expert-FUSION and Expert-TRACE, contributing to the biopsy suggestion.)
<psad>: noted: 0.267 (The PSA density was noted, as marked by the panel protocol, supporting the decision.)
My confidence in the record as it stands is clear, as all necessary documents were retrieved to address the moderator's queries.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the retrieved evidence, particularly the PI-RADS 5 and the PSA trend, strongly supports the panel's decision based on the cohort criterion.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

74 y/o male, biopsy-naive, PI-RADS 5 with PSA 7.93 and PSA density 0.267. The PI-RADS 5 finding warrants biopsy, supported by the elevated PSA density. No prior biopsy grade is recorded, but the new P5 finding dictates sampling.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
